Type 2 diabetes: tirzepatide approved in the US


The GLP-1/GIP dual receptor agonist tirzepatide, like most GLP-1 receptor agonists, is administered subcutaneously. The application takes place once a week. Like Glutide, Tirzepatid can cause nausea, Vomitdiarrhea, decreased appetite, constipation, upper abdominal discomfort and abdominal pain.

Source link

READ
7 foods that fill you up and help you lose weight
Previous Red Roses: Repetition of the 3562 series, season 19 online and on TV
Next Switzerland: Pharmacists and doctors are planning a uniform e-prescription solution